Therapy News and Research

RSS

Nevirapine reduces HIV transmission risk from mother to breastfeeding infants by 75%

Giving breastfeeding infants of HIV-infected mothers a daily dose of the antiretroviral drug nevirapine for six months halved the risk of HIV transmission to the infants at age 6 months compared with giving infants the drug daily for six weeks, according to preliminary clinical trial data presented today.

4 Mar 2011

Volcano launches Platinum digital IVUS catheter at PCI Live Demonstration Course in Kurashiki

Volcano Corporation, a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it received clearance to market the Eagle Eye Platinum digital IVUS catheter in Japan, and will introduce the device at the 20th PCI Live Demonstration Course in Kurashiki, which starts on March 3rd.

4 Mar 2011

Electrical stimulation may help bring back the voice of stroke patients

A Virginia Tech College of Engineering researcher is seeking a new way to help those who are unable to speak to find their voice. But this isn't "The King's Speech," the Academy Award-winning film about a British royal undergoing speech therapy to battle a stammer. Instead, Alexander Leonessa wants to help bring back the voice of stroke patients and others who have suffered paralysis of the vocal folds, through electrical stimulation.

4 Mar 2011

Triptolide isolated from Chinese medicinal plant blocks gene control machinery in cells

Researchers at the Johns Hopkins School of Medicine have discovered that a natural product isolated from a traditional Chinese medicinal plant commonly known as thunder god vine, or lei gong teng, and used for hundreds of years to treat many conditions including rheumatoid arthritis works by blocking gene control machinery in the cell. The report, published as a cover story of the March issue of Nature Chemical Biology, suggests that the natural product could be a starting point for developing new anticancer drugs.

4 Mar 2011

Results Physiotherapy opens new clinic in Collierville

Collierville now has a new choice for treating Orthopedic problems, sports injuries and a variety of conditions that cause pain. Results Physiotherapy has opened a new physical therapy clinic in Collierville, and it is the fifth location in the greater Memphis area.

4 Mar 2011

Ekomed to collaborate with Immune Network and Immunitor for further research of Immunoxel/Dzherelo

Immune Network Ltd. advises that Ukrainian company Ekomed LLC has agreed to collaborate with Immune Network and Immunitor for further clinical research of a tableted form of Ekomed's well-known immunomodulator herbal product Immunoxel/Dzherelo.

4 Mar 2011

Shire receives European Commission approval for self-administration of FIRAZYR for HAE

Shire plc, the global specialty biopharmaceutical company, today announced that the European Commission has approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. FIRAZYR is the first and only treatment for acute Type I and Type II hereditary angioedema (HAE) attacks licensed for self-administration in Europe.

4 Mar 2011

Special issue highlights need for specialist evaluation, conservative treatment of infants with DP

In the two decades since the start of "Back to Sleep" campaign, doctors and surgeons have seen a surge in the number of infants with position-related head deformities called deformational plagiocephaly.

4 Mar 2011

$Chemotherapy, endocrine therapy may increase risk of bone fractures in breast cancer survivors$

Chemotherapy, endocrine therapy may increase risk of bone fractures in breast cancer survivors

The combined effects of chemotherapy and endocrine therapy may increase the risk of bone fractures in breast cancer survivors.

4 Mar 2011

ATS releases new report detailing emerging trends in HIV-linked pulmonary disease management

The American Thoracic Society has released a new report detailing recent global changes in the management of human immunodeficiency virus-associated pulmonary disease.

4 Mar 2011

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).

4 Mar 2011

VDF urges Americans to learn about risks of DVT to help prevent death

Each year between 100,000-180,000 Americans die as the result of pulmonary embolism, a complication from blood clots in the lungs. The Vascular Disease Foundation urges Americans, especially women, to learn about the risks of venous blood clots to help prevent these deaths.

3 Mar 2011

BIOTRONIK launches new Renamic implantable cardiac device in Europe

BIOTRONIK SE & Co. KG announced today the European market launch of their new Renamic implantable cardiac device programmer. Renamic is the latest addition to BIOTRONIK's new portfolio of external devices launched within only a few months.

3 Mar 2011

VICC introduces nation's first personalized cancer decision support tool

Vanderbilt-Ingram Cancer Center has launched the nation's first personalized cancer decision support tool, "My Cancer Genome," to help physicians and researchers track the latest developments in personalized cancer medicine and connect with clinical research trials for their patients.

3 Mar 2011

Scientists uncover genetic pathway that affects breast cancer development

Using recent advances in genomics, researchers have uncovered a genetic pathway that affects the development of breast cancer, work that could help predict which patients are at risk of relapse for the disease.

3 Mar 2011

Ventus Medical's Provent Sleep Apnea Therapy granted CE Mark

Ventus Medical, Inc. a privately-held medical device company dedicated to providing novel products to treat sleep-disordered breathing, today announced that it has received CE Mark for its Provent® Sleep Apnea Therapy.

3 Mar 2011

Protalex initiates enrollment in 3rd cohort of PRTX-100 Phase 1b dose escalation clinical study in RA

Protalex, Inc, a clinical stage biopharmaceutical company which is engaged in developing a class of drugs for treating autoimmune and inflammatory diseases, today announced enrollment of the first patients in the 3rd cohort of its ongoing multicenter Phase 1b dose escalation clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA) being conducted in South Africa. The dose was increased by a factor of two from the 2nd cohort.

3 Mar 2011

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926 compared to placebo in patients with metastatic or locally advanced, inoperable chondrosarcoma. The trial is expected to enroll over 100 patients worldwide.

3 Mar 2011

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

Argos Therapeutics announced today that its Arcelis immunotherapy for the treatment of HIV, AGS-004, demonstrated positive outcomes with the primary endpoint of viral load control and a favorable safety and immunogenicity profile in a final analysis of a Phase 2a clinical trial.

3 Mar 2011

SAMHSA survey: 65% of substance abuse treatment facilities accept private health insurance

A new nationwide survey of substance abuse treatment facilities reveals that in 2008 nearly two thirds accepted some private health insurance payment.

3 Mar 2011

Therapy News and Research

Nevirapine reduces HIV transmission risk from mother to breastfeeding infants by 75%

Volcano launches Platinum digital IVUS catheter at PCI Live Demonstration Course in Kurashiki

Electrical stimulation may help bring back the voice of stroke patients

Triptolide isolated from Chinese medicinal plant blocks gene control machinery in cells

Results Physiotherapy opens new clinic in Collierville

Ekomed to collaborate with Immune Network and Immunitor for further research of Immunoxel/Dzherelo

Shire receives European Commission approval for self-administration of FIRAZYR for HAE

Special issue highlights need for specialist evaluation, conservative treatment of infants with DP

Chemotherapy, endocrine therapy may increase risk of bone fractures in breast cancer survivors

ATS releases new report detailing emerging trends in HIV-linked pulmonary disease management

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

VDF urges Americans to learn about risks of DVT to help prevent death

BIOTRONIK launches new Renamic implantable cardiac device in Europe

VICC introduces nation's first personalized cancer decision support tool

Scientists uncover genetic pathway that affects breast cancer development

Ventus Medical's Provent Sleep Apnea Therapy granted CE Mark

Protalex initiates enrollment in 3rd cohort of PRTX-100 Phase 1b dose escalation clinical study in RA

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

SAMHSA survey: 65% of substance abuse treatment facilities accept private health insurance

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News